HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Positive results for drug combo in I-SPY 2 trial.

Abstract
In results from one part of the I-SPY 2 trial announced at the 2013 San Antonio Breast Cancer Symposium, neoadjuvant veliparib plus carboplatin improved outcomes for women with triple-negative breast cancer.
Authors
JournalCancer discovery (Cancer Discov) Vol. 4 Issue 2 Pg. OF2 (Feb 2014) ISSN: 2159-8290 [Electronic] United States
PMID24501314 (Publication Type: News)
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Clinical Trials, Phase II as Topic
  • Female
  • Humans
  • Neoadjuvant Therapy
  • Triple Negative Breast Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: